NAT2

Summary

NAT2 (N-acetyltransferase 2, HGNC:7646) is a protein-coding gene on chromosome 8p22, encoding Arylamine N-acetyltransferase 2 (P11245). Catalyzes the N- or O-acetylation of various arylamine and heterocyclic amine substrates.

This gene encodes an enzyme that functions to both activate and deactivate arylamine and hydrazine drugs and carcinogens. Polymorphisms in this gene are responsible for the N-acetylation polymorphism in which human populations segregate into rapid, intermediate, and slow acetylator phenotypes. Polymorphisms in this gene are also associated with higher incidences of cancer and drug toxicity. A second polymorphic arylamine N-acetyltransferase gene (NAT1), is located near this gene (NAT2).

Source: NCBI Gene 10 — RefSeq curated summary.

At a glance

• Gene–disease (curated): acetylation, slow (Limited, GenCC)
• Clinical variants (ClinVar): 55 total
• Druggable target: yes
• MANE Select transcript: NM_000015

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:7646
Approved symbol	NAT2
Name	N-acetyltransferase 2
Location	8p22
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000156006
Ensembl biotype	protein_coding
OMIM	612182
Entrez	10

Gene structure

Transcript identifiers

Ensembl transcripts: 5 — 5 protein_coding

ENST00000286479, ENST00000520116, ENST00000893781, ENST00000893782, ENST00000893783

RefSeq mRNA: 1 — MANE Select: NM_000015 NM_000015

CCDS: CCDS6008

Canonical transcript exons

ENST00000286479 — 2 exons

Exon	Start	End
ENSE00001023867	18399998	18401218
ENSE00001344644	18391282	18391345

Expression profiles

Bgee: expression breadth ubiquitous, 131 present calls, max score 94.10.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.3695 / max 109.7155, expressed in 42 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
87571	0.2950	21
87570	0.0745	18

Top tissues by expression

271 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right lobe of liver	UBERON:0001114	94.10	gold quality
jejunal mucosa	UBERON:0000399	93.92	gold quality
liver	UBERON:0002107	91.05	gold quality
ileal mucosa	UBERON:0000331	89.81	gold quality
duodenum	UBERON:0002114	88.19	gold quality
mucosa of transverse colon	UBERON:0004991	87.33	gold quality
colonic mucosa	UBERON:0000317	87.11	gold quality
mucosa of sigmoid colon	UBERON:0004993	85.58	gold quality
rectum	UBERON:0001052	84.23	gold quality
small intestine	UBERON:0002108	72.96	gold quality
transverse colon	UBERON:0001157	72.49	gold quality
jejunum	UBERON:0002115	72.00	gold quality
small intestine Peyer’s patch	UBERON:0003454	71.81	gold quality
amniotic fluid	UBERON:0000173	66.92	gold quality
intestine	UBERON:0000160	66.03	gold quality
diaphragm	UBERON:0001103	65.40	gold quality
cervix squamous epithelium	UBERON:0006922	64.12	gold quality
vermiform appendix	UBERON:0001154	64.11	gold quality
cardiac muscle of right atrium	UBERON:0003379	64.11	gold quality
left ventricle myocardium	UBERON:0006566	63.90	gold quality
large intestine	UBERON:0000059	63.47	gold quality
caecum	UBERON:0001153	63.08	gold quality
smooth muscle tissue	UBERON:0001135	63.07	gold quality
colon	UBERON:0001155	62.38	gold quality
endometrium epithelium	UBERON:0004811	61.22	gold quality
choroid plexus epithelium	UBERON:0003911	60.99	gold quality
secondary oocyte	CL:0000655	60.81	silver quality
placenta	UBERON:0001987	60.69	gold quality
metanephros cortex	UBERON:0010533	59.50	gold quality
metanephros	UBERON:0000081	57.86	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	2.57

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): NR3C1

miRNA regulators (miRDB)

33 targeting NAT2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6758-5P	100.00	66.21	1470
HSA-MIR-6856-5P	100.00	65.47	1298
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-551B-5P	99.96	71.28	3493
HSA-MIR-548AT-5P	99.96	70.83	2666
HSA-MIR-6755-5P	99.95	65.59	464
HSA-MIR-9718	99.94	68.91	918
HSA-MIR-153-5P	99.89	73.86	6317
HSA-MIR-6875-3P	99.82	70.26	2983
HSA-MIR-4307	99.82	70.45	3374
HSA-MIR-4659A-3P	99.80	72.62	4248
HSA-MIR-4659B-3P	99.80	72.62	4248
HSA-MIR-4699-3P	99.71	70.15	3142
HSA-MIR-651-5P	99.64	68.49	1104
HSA-MIR-7159-5P	99.53	72.12	2472
HSA-MIR-12123	99.52	71.79	2990
HSA-MIR-4452	99.50	68.45	1493
HSA-MIR-16-2-3P	99.29	70.60	1954
HSA-MIR-195-3P	99.29	70.61	1954
HSA-MIR-664A-3P	99.22	71.08	2696
HSA-MIR-4801	98.96	69.42	2096
HSA-MIR-4731-3P	98.56	68.60	1860
HSA-MIR-532-5P	98.43	67.53	760
HSA-MIR-628-5P	98.36	67.74	844
HSA-MIR-1262	98.17	66.52	757
HSA-MIR-4701-3P	98.17	66.25	788
HSA-MIR-6736-5P	98.17	66.43	760
HSA-MIR-585-5P	97.54	69.02	955

Literature-anchored findings (GeneRIF, showing 2)

• central folding motif of the gp10 trimer is similar to that of the baseplate protein gp11 and to the receptor-binding domain of the short tail fiber, gp12 (PMID:16554069)
• The connector protein increases both the yield and the rate of capsid assembly suggesting that the incorporation of the connector in Phi29 likely promotes nucleation of assembly. (PMID:19744688)

Cross-species orthologs

8 orthologs

Organism	Symbol	Gene ID
danio_rerio	zgc:101040	ENSDARG00000005176
danio_rerio	si:dkey-78a14.4	ENSDARG00000036066
mus_musculus	Nat1	ENSMUSG00000025588
mus_musculus	Nat2	ENSMUSG00000051147
mus_musculus	Nat3	ENSMUSG00000056426
rattus_norvegicus	Nat3	ENSRNOG00000029977
rattus_norvegicus	Nat2	ENSRNOG00000049498
rattus_norvegicus	Nat3	ENSRNOG00000074135

Paralogs (1): NAT1 (ENSG00000171428)

Protein

Protein identifiers

Arylamine N-acetyltransferase 2 — P11245 (reviewed: P11245)

Alternative names: Arylamide acetylase 2, N-acetyltransferase type 2, N-hydroxyarylamine O-acetyltransferase, Polymorphic arylamine N-acetyltransferase

All UniProt accessions (3): P11245, A4Z6T7, E7EWF9

UniProt curated annotations — full annotation on UniProt →

Function. Catalyzes the N- or O-acetylation of various arylamine and heterocyclic amine substrates. Participates in the detoxification of a plethora of hydrazine and arylamine drugs, and is able to bioactivate several known carcinogens.

Subcellular location. Cytoplasm.

Polymorphism. Genetic variations in NAT2 determine the rate of acetylation of various arylamine and heterocyclic amine substrates that include therapeutic and carcinogenic agents. They influence drug therapy response and susceptibility to chemical toxicity [MIM:243400]. Different alleles are known, whose combination defines the rapid, intermediate and slow acetylator phenotypes. Allele NAT24 sequence is historically considered as the reference in most publications. The sequence shown in this entry corresponds to the translation of allele NAT212A, which is the one represented in the human reference genome (GRCh38/hg38 assembly) and has an arginine at position 268 (Ref.7). The enzyme encoded by allele NAT2*4 differs by the variant p.Arg268Lys. The two alloenzymes have comparable arylamine N-acetyltransferase activity.

Similarity. Belongs to the arylamine N-acetyltransferase family.

RefSeq proteins (1): NP_000006* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001447	Arylamine_N-AcTrfase	Family
IPR038765	Papain-like_cys_pep_sf	Homologous_superfamily
IPR053710	Arylamine_NAT_domain_sf	Homologous_superfamily

Pfam: PF00797

Enzyme classification (BRENDA):

• EC 2.3.1.5 — arylamine N-acetyltransferase (BRENDA: 76 organisms, 504 substrates, 242 inhibitors, 322 Km, 150 kcat entries)

Substrate kinetics (BRENDA)

91 substrates with measured Km, best-characterized 15. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
2-AMINOFLUORENE	0.0002–5.8	50
ACETYL-COA	0.0084–560	23
5-AMINOSALICYLIC ACID	0.0067–1.7	16
ISONIAZID	0.18–102	14
P-AMINOBENZOIC ACID	0.0028–152	13
SULFAMETHAZINE	0.02–5.39	11
4-NITROPHENYL ACETATE	0.164–10	9
HYDRALAZINE	0.0134–1.327	9
4-AMINOSALICYLATE	0.0941–3.827	8
4-AMINOSALICYLIC ACID	0.258–2.2	8
4-AMINOBENZOIC ACID	0.049–166	7
5-AMINOSALICYLATE	0.2–0.662	7
4-AMINOBIPHENYL	0.0058–1.57	5
P-AMINOSALICYLIC ACID	0.059–5.39	5
4-AMINOBENZOATE	0.052–2.42	4

Catalyzed reactions (Rhea), 2 shown:

• an arylamine + acetyl-CoA = an N-acetylarylamine + CoA (RHEA:16613)
• an N-hydroxyarylamine + acetyl-CoA = an N-acetoxyarylamine + CoA (RHEA:20277)

UniProt features (56 total): sequence variant 18, strand 13, helix 12, binding site 6, active site 3, sequence conflict 3, chain 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
2PFR	X-RAY DIFFRACTION	1.92

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P11245-F1	96.62	0.94

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (3): 68 (acyl-thioester intermediate); 107; 122

Ligand- & substrate-binding residues (6): 103; 104; 106–107; 208; 214; 287

Function

Pathways and Gene Ontology

Reactome pathways

6 pathways

ID	Pathway
R-HSA-156582	Acetylation
R-HSA-9753281	Paracetamol ADME
R-HSA-1430728	Metabolism
R-HSA-156580	Phase II - Conjugation of compounds
R-HSA-211859	Biological oxidations
R-HSA-9748784	Drug ADME

MSigDB gene sets: 72 (showing top): REACTOME_BIOLOGICAL_OXIDATIONS, SHETH_LIVER_CANCER_VS_TXNIP_LOSS_PAM4, ACEVEDO_LIVER_TUMOR_VS_NORMAL_ADJACENT_TISSUE_DN, HSIAO_LIVER_SPECIFIC_GENES, CAIRO_HEPATOBLASTOMA_DN, MODULE_99, MODULE_112, CHIANG_LIVER_CANCER_SUBCLASS_PROLIFERATION_DN, KEGG_DRUG_METABOLISM_OTHER_ENZYMES, GOMF_ACETYLTRANSFERASE_ACTIVITY, GOMF_ACYLTRANSFERASE_ACTIVITY, GOMF_O_ACYLTRANSFERASE_ACTIVITY, GOMF_N_ACYLTRANSFERASE_ACTIVITY, REACTOME_PHASE_II_CONJUGATION_OF_COMPOUNDS, GOMF_N_ACETYLTRANSFERASE_ACTIVITY

GO Biological Process (1): xenobiotic metabolic process (GO:0006805)

GO Molecular Function (6): arylamine N-acetyltransferase activity (GO:0004060), N-hydroxyarylamine O-acetyltransferase activity (GO:0046990), protein binding (GO:0005515), acetyltransferase activity (GO:0016407), transferase activity (GO:0016740), acyltransferase activity (GO:0016746)

GO Cellular Component (3): cytosol (GO:0005829), cytoplasm (GO:0005737), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-4 pathways:

Category	Pathways
Phase II - Conjugation of compounds	1
Drug ADME	1
Biological oxidations	1
Metabolism	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
metabolic process	1
cellular response to xenobiotic stimulus	1
N-acetyltransferase activity	1
O-acetyltransferase activity	1
binding	1
acyltransferase activity, transferring groups other than amino-acyl groups	1
catalytic activity	1
transferase activity	1
cytoplasm	1
intracellular anatomical structure	1

Protein interactions and networks

STRING

840 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
NAT2	AADAC	P22760	865
NAT2	CYP2D6	P10635	783
NAT2	ESCO1	Q5FWF5	774
NAT2	GSTM1	P09488	772
NAT2	ESCO2	Q56NI9	770
NAT2	GATD3	P0DPI2	767
NAT2	CYP1A2	P05177	716
NAT2	CYP2E1	P05181	670
NAT2	UGT1A1	P22309	590
NAT2	UGT1A6	P19224	586
NAT2	UGT1A7	Q9HAW7	586
NAT2	PPIG	Q13427	585
NAT2	CYP1A1	P04798	585
NAT2	UGT1A4	P22310	585
NAT2	UGT1A10	Q9HAW8	584
NAT2	UGT1A8	Q9HAW9	584

IntAct

28 interactions, top by confidence:

A	B	Type	Score
MBD4	NAT2	psi-mi:“MI:0915”(physical association)	0.560
NAT2	RAD51	psi-mi:“MI:0915”(physical association)	0.540
NAT2	RAD51	psi-mi:“MI:0403”(colocalization)	0.540
RAD51	NAT2	psi-mi:“MI:0915”(physical association)	0.540
NAT2	STARD7	psi-mi:“MI:0914”(association)	0.530
ATM	NAT2	psi-mi:“MI:0915”(physical association)	0.510
NAT2	ATM	psi-mi:“MI:0915”(physical association)	0.510
NAT2	H1-2	psi-mi:“MI:0915”(physical association)	0.400
NAT2	PTBP1	psi-mi:“MI:0915”(physical association)	0.400
APC	NAT2	psi-mi:“MI:0915”(physical association)	0.370
NAT2	AURKA	psi-mi:“MI:0915”(physical association)	0.370
NAT2	BAG4	psi-mi:“MI:0915”(physical association)	0.370
NAT2	CDH1	psi-mi:“MI:0915”(physical association)	0.370
NAT2	CDKN2A	psi-mi:“MI:0915”(physical association)	0.370
CDKN2C	NAT2	psi-mi:“MI:0915”(physical association)	0.370
ERBB2	NAT2	psi-mi:“MI:0915”(physical association)	0.370
HMMR	NAT2	psi-mi:“MI:0915”(physical association)	0.370
IGF1R	NAT2	psi-mi:“MI:0915”(physical association)	0.370
NBN	NAT2	psi-mi:“MI:0915”(physical association)	0.370
NAT2	PALB2	psi-mi:“MI:0915”(physical association)	0.370
PPM1D	NAT2	psi-mi:“MI:0915”(physical association)	0.370
NAT2	STK11	psi-mi:“MI:0915”(physical association)	0.370
WT1	NAT2	psi-mi:“MI:0915”(physical association)	0.370
NAT2	MBD4	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (32): STARD7 (Affinity Capture-MS), ZNF346 (Affinity Capture-MS), KLK5 (Affinity Capture-MS), NAT2 (Two-hybrid), NAT2 (Two-hybrid), NAT2 (Two-hybrid), NAT2 (Two-hybrid), NAT2 (Two-hybrid), NAT2 (Two-hybrid), NAT2 (Two-hybrid), NAT2 (Two-hybrid), NAT2 (Two-hybrid), NAT2 (Two-hybrid), NAT2 (Two-hybrid), NAT2 (Two-hybrid)

ESM2 similar proteins: A0A179H324, A0A1B4XBK1, A0A1Y1C7Q5, A0A286LEZ6, A0A346RP51, A0A397HQ89, A0A8F4PN06, A8C7S0, B2DFU4, B7SP66, C9K1M7, C9K7B8, D4AK46, D4D447, G0LET6, G0LET9, I1R9B1, K3UFY2, K3VCL0, M1W268, O62696, O74516, O93801, P0CI62, P0DPA8, P0DUL5, P11245, P11246, P18440, P18605, P40483, P41929, P46580, P50292, P50293, P50294, P50295, P50296, P50297, P50298

Diamond homologs: O62696, P11245, P11246, P12275, P13913, P13914, P18440, P18605, P50292, P50293, P50294, P50295, P50296, P50297, P50298, Q00267, Q1JPA6, Q7YRG5, K3VCL0, Q5UPV4, B7SP66, O86309, W7NDP8

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 20 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Regulation of TP53 Activity	5	33.2×	1e-05
Transcriptional Regulation by TP53	5	15.5×	3e-04
Cellular responses to stress	5	9.2×	3e-03
Cell Cycle	5	9.0×	3e-03
Cellular responses to stimuli	5	7.9×	3e-03

GO biological processes:

GO term	Partners	Fold	FDR
negative regulation of cell population proliferation	6	12.6×	9e-04
negative regulation of apoptotic process	6	10.4×	9e-04

Disease & clinical

Clinical variants and AI predictions

ClinVar

55 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	40
Likely benign	6
Benign	4

Top pathogenic / likely-pathogenic (0)

SpliceAI

0 predictions. Top by Δscore:

AlphaMissense

1912 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
8:18400253:T:C	F84L	0.931
8:18400255:T:A	F84L	0.931
8:18400255:T:G	F84L	0.931
8:18400672:T:G	C223W	0.911
8:18400577:T:C	F192L	0.905
8:18400579:T:A	F192L	0.905
8:18400579:T:G	F192L	0.905
8:18400814:T:C	F271L	0.900
8:18400816:T:A	F271L	0.900
8:18400816:T:G	F271L	0.900
8:18400670:T:C	C223R	0.899
8:18400451:T:C	F150L	0.898
8:18400453:C:A	F150L	0.898
8:18400453:C:G	F150L	0.898
8:18400607:T:C	F202L	0.892
8:18400609:T:A	F202L	0.892
8:18400609:T:G	F202L	0.892
8:18400239:T:C	L79P	0.891
8:18400733:T:C	F244L	0.888
8:18400735:C:A	F244L	0.888
8:18400735:C:G	F244L	0.888
8:18400169:T:C	F56L	0.886
8:18400171:T:A	F56L	0.886
8:18400171:T:G	F56L	0.886
8:18400578:T:C	F192S	0.873
8:18400254:T:C	F84S	0.868
8:18400116:A:T	E38V	0.867
8:18400194:G:C	R64P	0.863
8:18400086:T:C	L28P	0.856
8:18400107:T:A	V35D	0.855

dbSNP variants (sampled 300 via entrez): RS1000271815 (8:18387258 G>A), RS1000455899 (8:18392238 A>C), RS1000640435 (8:18398518 C>A,T), RS1000682471 (8:18386525 A>G), RS1000942609 (8:18391719 C>G,T), RS1001103775 (8:18396976 T>C), RS1001191305 (8:18386743 TTC>T), RS1001197853 (8:18393313 A>C,G), RS1001287849 (8:18397279 C>G), RS1001517431 (8:18396979 A>G), RS1001632289 (8:18391988 A>T), RS1001801177 (8:18386273 CTT>C), RS1001912405 (8:18392775 G>A), RS1002135860 (8:18398030 G>C), RS1002323984 (8:18396428 T>A,C,G)

Disease associations

OMIM: gene MIM:612182 | disease phenotypes: MIM:243400

GenCC curated gene-disease

Disease	Classification	Inheritance
acetylation, slow	Limited	Autosomal recessive

Mondo (1): acetylation, slow (MONDO:0009472)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL2194 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=true)

CTD chemical–gene interactions

111 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Isoniazid	affects metabolic processing, affects acetylation, decreases acetylation, increases acetylation, increases metabolic processing (+4 more)	16
Caffeine	increases acetylation, affects metabolic processing	8
Sulfamethazine	affects acetylation, increases acetylation, increases metabolic processing	6
4-biphenylamine	increases activity, increases metabolic processing, affects response to substance, affects reaction, increases mutagenesis (+1 more)	5
Sulfasalazine	affects metabolic processing, affects response to substance, increases acetylation, increases metabolic processing	5
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline	increases response to substance, increases metabolic processing, increases expression, affects activity, affects chemical synthesis (+1 more)	4
2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine	increases activity, affects activity, affects chemical synthesis, decreases expression, increases expression	4
Amines	affects metabolic processing, increases activity, decreases activity, increases acetylation	4
2-aminofluorene	increases acetylation, increases metabolic processing	3
2-amino-3-methylimidazo(4,5-f)quinoline	affects cotreatment, increases response to substance, increases metabolic processing, increases mutagenesis	3
2-amino-3,4-dimethylimidazo(4,5-f)quinoline	affects cotreatment, increases response to substance, increases metabolic processing, affects activity, affects chemical synthesis	3
3-nitrobenzanthrone	affects cotreatment, increases mutagenesis, increases activity, increases reaction, increases reduction (+1 more)	3
Benzo(a)pyrene	increases expression, decreases expression, increases methylation, affects cotreatment	3
Valproic Acid	affects expression, increases expression	3
Aflatoxin B1	decreases expression, increases expression, affects cotreatment, increases response to substance	3
trichostatin A	affects cotreatment, increases expression	2
2-amino-3-methyl-9H-pyrido(2,3-b)indole	increases activity, increases metabolic processing, increases response to substance	2
2-amino-9H-pyrido(2,3-b)indole	affects binding, affects cotreatment, increases mutagenesis, increases reaction, affects response to substance (+2 more)	2
2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine	increases acetylation, increases metabolic processing	2
dimethocaine	increases acetylation, increases response to substance, increases expression	2
9-(4’-aminophenyl)-9H-pyrido(3,4-b)indole	affects metabolic processing, increases metabolic processing, increases response to substance	2
Acetaminophen	decreases expression	2
Calcitriol	decreases expression, increases expression, affects cotreatment	2
Estradiol	decreases expression	2
Glucose	increases expression, affects activity, affects chemical synthesis, increases activity	2
Polycyclic Aromatic Hydrocarbons	affects secretion, increases acetylation	2
2-Naphthylamine	increases activity, affects reaction, increases mutagenesis, affects acetylation, increases acetylation	2
Cyclosporine	decreases expression	2
N-hydroxy-4-acetylaminobiphenyl	decreases activity	1
2-anisidine	increases activity	1

ChEMBL screening assays

2 unique, capped per target: 2 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL3267124	Binding	Inhibition of human NAT2 assessed as rate of free thiol coenzyme A production using arylamine and AcCoA as substrate at 30 uM by Ellman’s method	Structure-activity relationships and colorimetric properties of specific probes for the putative cancer biomarker human arylamine N-acetyltransferase 1. — Bioorg Med Chem

Cellosaurus cell lines

13 cell lines: 13 spontaneously immortalized cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_8559	YG10008	Spontaneously immortalized cell line	Female
CVCL_A2HA	V79MZh1A2/hNAT2	Spontaneously immortalized cell line	Male
CVCL_UU81	CHL ANP-19	Spontaneously immortalized cell line	Female
CVCL_UU82	CHL ANP-25	Spontaneously immortalized cell line	Female
CVCL_UU83	CHL ANP-38	Spontaneously immortalized cell line	Female
CVCL_UU84	CHL CNP-16	Spontaneously immortalized cell line	Female
CVCL_UU85	CHL CNP-26	Spontaneously immortalized cell line	Female
CVCL_UU86	CHL CNP-40	Spontaneously immortalized cell line	Female
CVCL_UV01	CHL 7P-101	Spontaneously immortalized cell line	Female
CVCL_UV02	CHL 7P-142	Spontaneously immortalized cell line	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.